

Ovarian Cancer (Epithelial) Pathways

Patient Name: _____ Date of Birth: _____

Member Number: _____ Treatment Start Date: _____

Pathology: _____ Stage: _____

Line of Therapy: __Neoadjuvant/Pre-Op __Adjuvant/Post-Op ECOG Performance Status: _____ ICD-10 Code: _____

1st Line 2nd Line 3rd Line 3rd Line+ Maintenance

Biomarkers/Characteristics: (Select all that apply)

BRCA1 Status: Germline Mutation Wild Type (no mutation)

Somatic Mutation Not Reported

BRCA2 Status: Germline Mutation Wild Type (no mutation)

Somatic Mutation Not Reported

Platinum Sensitive*: Yes No Not Reported

Platinum Refractory/Resistant: Yes No Not Reported

Adjuvant Therapy | Stage IA/B (Grade 2 or 3) or IC (Grade 1-3)

Carboplatin and dose dense paclitaxel

Carboplatin and paclitaxel

Adjuvant or Primary Therapy | Stage II, III, IV

Carboplatin and paclitaxel (**Administered weekly or every 3 weeks**)

Intravenous (IV) paclitaxel and Intraperitoneal (IP) cisplatin and IP paclitaxel (**Stage III only**)

Recurrent Disease | First and Subsequent Lines of Therapy (1st Line+) | Platinum-Sensitive*

Carboplatin

Carboplatin and gemcitabine (Gemzar)

Carboplatin and paclitaxel

Carboplatin and weekly paclitaxel

Recurrent Disease | Maintenance Therapy | Platinum-Sensitive*

Niraparib (Zejula)

Olaparib (Lynparza)

Rucaparib (Rubraca)

Recurrent Disease | Second and Subsequent Lines of Therapy (2nd Line+) | Platinum Resistant

Bevacizumab (Avastin) monotherapy

Docetaxel (Taxotere)

Gemcitabine (Gemzar)

Liposomal doxorubicin (Doxil or Lipodox)

Paclitaxel (weekly)

Paclitaxel and bevacizumab (Avastin)

Tamoxifen

Topotecan (Hycamtin)

Topotecan (Hycamtin) and bevacizumab (Avastin)

Vinorelbine (Navelbine)

*Platinum sensitive disease is defined as recurrence of greater than 6 months after prior platinum-based therapy

Note: Pathways are independent of specific health plan medical policy coverage criteria. Health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars of reference products listed are considered "on pathway." However, reimbursement for biosimilar products may be impacted by health plan specific formularies, medical policy and preferred product rules.



8600 West Bryn Mawr Avenue
South Tower - Suite 800 Chicago, IL 60631
www.aimspecialtyhealth.com

Last review: 8/27/2019 | Effective date: 11/18/2019

Appropriate.Safe.Affordable

© 2019 AIM Specialty Health
9018-1119